A Study of AL102 in Patients With Progressing Desmoid Tumors
← catalyst calendarSponsored by Immunome, Inc. (industry) · IMNM — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
198actual
Sites
53
Countries
Australia, Belgium, Germany +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-01 | actual | When the study began enrolling |
| Primary completion | 2025-12-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Desmoid
- Desmoid Tumor
Interventions
- Drug: AL102 — also filed as varegacestat
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Safety and Tolerability - Adverse Events
measured Approximately 1.5 years
Part B: Progression free survival (PFS)
measured Approximately 2 years
Permalink · IMNM's whole pipeline · Catalyst calendar · Every registered study · What changed